SARS-CoV-2 Breakthrough Infections among US Embassy Staff Members, Uganda, May–June 2021
Julie R. Harris
, Daniel Owusu, Kevin O’Laughlin, Adam L. Cohen, Amen Ben Hamida, Jaymin C. Patel, Molly M. Freeman, Thomas Nsibambi, Rebecca Nieves, Barbara J. Marston, Samuel Wasike, Jennifer S. Galbraith, Amy L. Boore, Lisa J. Nelson, Sarah Anne J. Guagliardo, John D. Klena, Ketan Patel, and Marek Ma
Author affiliations: Centers for Disease Control and Prevention, Kampala, Uganda (J.R. Harris, T. Nsibambi, S. Wasike, J.S. Galbraith, A.L. Boore, L.J. Nelson); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D. Owusu, K. O’Laughlin, A.L. Cohen, A.B. Hamida, J.C. Patel, M.M. Freeman, B.J. Marston, S.A.J. Guagliardo, J.D. Klena, K. Patel); US Department of State, Kampala (R. Nieves, M. Ma)
Figure. Dates of first COVID-19 vaccine dose, second vaccine dose, and positive SARS-CoV-2 test among 19 staff, family members, and visiting US government staff with identified postvaccination SARS-CoV-2 infection, US Embassy, Kampala, Uganda, 2021. Among 20 persons with breakthrough infections, 19 consented to have their data included.
Page created: April 14, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.